Financhill
Sell
49

INSM Quote, Financials, Valuation and Earnings

Last price:
$67.17
Seasonality move :
7.06%
Day range:
$65.32 - $67.22
52-week range:
$21.92 - $84.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.36x
P/B ratio:
123.47x
Volume:
1.2M
Avg. volume:
2.7M
1-year change:
169.64%
Market cap:
$12.2B
Revenue:
$363.7M
EPS (TTM):
-$5.95

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
INSM
Insmed
$91.2M -$1.36 14.35% -32.94% $96.78
ARDX
Ardelyx
$79.4M -$0.08 13.1% -94.66% $10.32
BAX
Baxter International
$2.6B $0.48 -25.95% 590.29% $38.68
BBIO
BridgeBio Pharma
$57.7M -$1.00 4530.37% -18.53% $58.78
BMRN
Biomarin Pharmaceutical
$738.7M $0.95 7% 86.93% $95.87
FOLD
Amicus Therapeutics
$136.3M $0.08 16.44% -80% $15.82
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
INSM
Insmed
$67.22 $96.78 $12.2B -- $0.00 0% 30.36x
ARDX
Ardelyx
$3.38 $10.32 $808.7M -- $0.00 0% 2.21x
BAX
Baxter International
$31.04 $38.68 $15.9B 167.20x $0.17 2.96% 1.34x
BBIO
BridgeBio Pharma
$33.74 $58.78 $6.4B -- $0.00 0% 50.03x
BMRN
Biomarin Pharmaceutical
$58.27 $95.87 $11.2B 21.66x $0.00 0% 3.91x
FOLD
Amicus Therapeutics
$5.95 $15.82 $1.8B -- $0.00 0% 3.35x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
INSM
Insmed
91.77% 5.850 7.96% 5.21x
ARDX
Ardelyx
50.95% 1.385 12.88% 3.43x
BAX
Baxter International
58.72% 0.052 57.45% 1.13x
BBIO
BridgeBio Pharma
925.32% 1.067 28.12% 4.31x
BMRN
Biomarin Pharmaceutical
9.32% -0.133 4.39% 3.20x
FOLD
Amicus Therapeutics
66.87% 0.483 15.55% 2.22x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
INSM
Insmed
$71.5M -$229.8M -85.3% -1146.32% -254.17% -$272.2M
ARDX
Ardelyx
$61.8M -$36.3M -19.51% -34.68% -45.91% -$38.8M
BAX
Baxter International
$861M $58M -2.78% -7.38% 2.97% -$315M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
BMRN
Biomarin Pharmaceutical
$593.6M $223.9M 8.4% 9.62% 32.34% $157.6M
FOLD
Amicus Therapeutics
$113.6M -$8M -5.29% -17.7% -5.26% $7.5M

Insmed vs. Competitors

  • Which has Higher Returns INSM or ARDX?

    Ardelyx has a net margin of -276.42% compared to Insmed's net margin of -55.52%. Insmed's return on equity of -1146.32% beat Ardelyx's return on equity of -34.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    77.08% -$1.42 $1.2B
    ARDX
    Ardelyx
    83.4% -$0.17 $297M
  • What do Analysts Say About INSM or ARDX?

    Insmed has a consensus price target of $96.78, signalling upside risk potential of 43.98%. On the other hand Ardelyx has an analysts' consensus of $10.32 which suggests that it could grow by 205.27%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    13 0 0
    ARDX
    Ardelyx
    8 2 0
  • Is INSM or ARDX More Risky?

    Insmed has a beta of 0.837, which suggesting that the stock is 16.28% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.762, suggesting its less volatile than the S&P 500 by 23.846%.

  • Which is a Better Dividend Stock INSM or ARDX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or ARDX?

    Insmed quarterly revenues are $92.8M, which are larger than Ardelyx quarterly revenues of $74.1M. Insmed's net income of -$256.6M is lower than Ardelyx's net income of -$41.1M. Notably, Insmed's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 30.36x versus 2.21x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    30.36x -- $92.8M -$256.6M
    ARDX
    Ardelyx
    2.21x -- $74.1M -$41.1M
  • Which has Higher Returns INSM or BAX?

    Baxter International has a net margin of -276.42% compared to Insmed's net margin of 4.8%. Insmed's return on equity of -1146.32% beat Baxter International's return on equity of -7.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    77.08% -$1.42 $1.2B
    BAX
    Baxter International
    32.8% $0.25 $17.1B
  • What do Analysts Say About INSM or BAX?

    Insmed has a consensus price target of $96.78, signalling upside risk potential of 43.98%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 24.61%. Given that Insmed has higher upside potential than Baxter International, analysts believe Insmed is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    13 0 0
    BAX
    Baxter International
    4 11 1
  • Is INSM or BAX More Risky?

    Insmed has a beta of 0.837, which suggesting that the stock is 16.28% less volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

  • Which is a Better Dividend Stock INSM or BAX?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.96% to investors and pays a quarterly dividend of $0.17 per share. Insmed pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BAX?

    Insmed quarterly revenues are $92.8M, which are smaller than Baxter International quarterly revenues of $2.6B. Insmed's net income of -$256.6M is lower than Baxter International's net income of $126M. Notably, Insmed's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 30.36x versus 1.34x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    30.36x -- $92.8M -$256.6M
    BAX
    Baxter International
    1.34x 167.20x $2.6B $126M
  • Which has Higher Returns INSM or BBIO?

    BridgeBio Pharma has a net margin of -276.42% compared to Insmed's net margin of -143.55%. Insmed's return on equity of -1146.32% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    77.08% -$1.42 $1.2B
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About INSM or BBIO?

    Insmed has a consensus price target of $96.78, signalling upside risk potential of 43.98%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 74.21%. Given that BridgeBio Pharma has higher upside potential than Insmed, analysts believe BridgeBio Pharma is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    13 0 0
    BBIO
    BridgeBio Pharma
    10 3 0
  • Is INSM or BBIO More Risky?

    Insmed has a beta of 0.837, which suggesting that the stock is 16.28% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

  • Which is a Better Dividend Stock INSM or BBIO?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BBIO?

    Insmed quarterly revenues are $92.8M, which are smaller than BridgeBio Pharma quarterly revenues of $116.6M. Insmed's net income of -$256.6M is lower than BridgeBio Pharma's net income of -$167.4M. Notably, Insmed's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 30.36x versus 50.03x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    30.36x -- $92.8M -$256.6M
    BBIO
    BridgeBio Pharma
    50.03x -- $116.6M -$167.4M
  • Which has Higher Returns INSM or BMRN?

    Biomarin Pharmaceutical has a net margin of -276.42% compared to Insmed's net margin of 24.92%. Insmed's return on equity of -1146.32% beat Biomarin Pharmaceutical's return on equity of 9.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    77.08% -$1.42 $1.2B
    BMRN
    Biomarin Pharmaceutical
    79.66% $0.95 $6.4B
  • What do Analysts Say About INSM or BMRN?

    Insmed has a consensus price target of $96.78, signalling upside risk potential of 43.98%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.87 which suggests that it could grow by 64.53%. Given that Biomarin Pharmaceutical has higher upside potential than Insmed, analysts believe Biomarin Pharmaceutical is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    13 0 0
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is INSM or BMRN More Risky?

    Insmed has a beta of 0.837, which suggesting that the stock is 16.28% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

  • Which is a Better Dividend Stock INSM or BMRN?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or BMRN?

    Insmed quarterly revenues are $92.8M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Insmed's net income of -$256.6M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Insmed's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 30.36x versus 3.91x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    30.36x -- $92.8M -$256.6M
    BMRN
    Biomarin Pharmaceutical
    3.91x 21.66x $745.1M $185.7M
  • Which has Higher Returns INSM or FOLD?

    Amicus Therapeutics has a net margin of -276.42% compared to Insmed's net margin of -17.31%. Insmed's return on equity of -1146.32% beat Amicus Therapeutics's return on equity of -17.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    INSM
    Insmed
    77.08% -$1.42 $1.2B
    FOLD
    Amicus Therapeutics
    90.66% -$0.07 $584.3M
  • What do Analysts Say About INSM or FOLD?

    Insmed has a consensus price target of $96.78, signalling upside risk potential of 43.98%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 165.85%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    INSM
    Insmed
    13 0 0
    FOLD
    Amicus Therapeutics
    8 3 0
  • Is INSM or FOLD More Risky?

    Insmed has a beta of 0.837, which suggesting that the stock is 16.28% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

  • Which is a Better Dividend Stock INSM or FOLD?

    Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios INSM or FOLD?

    Insmed quarterly revenues are $92.8M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Insmed's net income of -$256.6M is lower than Amicus Therapeutics's net income of -$21.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 30.36x versus 3.35x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    INSM
    Insmed
    30.36x -- $92.8M -$256.6M
    FOLD
    Amicus Therapeutics
    3.35x -- $125.2M -$21.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Is Acuity a Good Stock to Buy Now?
Is Acuity a Good Stock to Buy Now?

Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
59
RGC alert for May 16

Regencell Bioscience Holdings [RGC] is up 16.91% over the past day.

Buy
89
BOOT alert for May 16

Boot Barn Holdings [BOOT] is up 16.55% over the past day.

Sell
43
FI alert for May 16

Fiserv [FI] is down 16.2% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock